Professor | Yanmin Zhao | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Yanmin Zhao
Contact Information	zjzhaoyanmin@163.com
Language ability	Chinese, English
Province	Zhejiang

Upload Avatar (500 x 500)

Name

Yanmin Zhao

Contact Information

zjzhaoyanmin@163.com

Language ability

Chinese, English

Province

Zhejiang

University/Lab Affiliation and Title	Zhejiang University
Faculty	Medical
Academic Background & Achievements	2005/9–2009/6 PhD in Hematology: Zhejiang University 2005/7–2005/9 Summer Research Program: UCLA 2000/9–2005/7 Bachelor's in Clinical Medicine: Zhejiang University Achievement: Published over 50 SCI papers as first or corresponding author Achievement: Delivered invited and oral presentations at ASH, EHA, EBMT, APBMT
Work Experience	2023/10-present - Liangzhu Laboratory - Distinguished Researcher 2022/10-present - Zhejiang University, First Affiliated Hospital - Distinguished Researcher 2020/1-present - Zhejiang University, First Affiliated Hospital - Chief Physician 2016/1-2020/12 - Zhejiang University, First Affiliated Hospital - Associate Chief Physician 2010/5-2015/12 - Zhejiang University, First Affiliated Hospital - Attending Physician 2009/8-2010/5 - Zhejiang University, First Affiliated Hospital - Resident Physician
Awards	2019: Zhejiang Immunology Society Zhijiang Outstanding Young Scholar Zhejiang Province 551 Talent Project Medical Rookie

University/Lab Affiliation and Title

Zhejiang University

Faculty

Medical

Academic Background & Achievements

2005/9–2009/6 PhD in Hematology: Zhejiang University
2005/7–2005/9 Summer Research Program: UCLA
2000/9–2005/7 Bachelor's in Clinical Medicine: Zhejiang University
Achievement: Published over 50 SCI papers as first or corresponding author
Achievement: Delivered invited and oral presentations at ASH, EHA, EBMT, APBMT

Work Experience

2023/10-present - Liangzhu Laboratory - Distinguished Researcher
2022/10-present - Zhejiang University, First Affiliated Hospital - Distinguished Researcher
2020/1-present - Zhejiang University, First Affiliated Hospital - Chief Physician
2016/1-2020/12 - Zhejiang University, First Affiliated Hospital - Associate Chief Physician
2010/5-2015/12 - Zhejiang University, First Affiliated Hospital - Attending Physician
2009/8-2010/5 - Zhejiang University, First Affiliated Hospital - Resident Physician

Awards

2019: Zhejiang Immunology Society Zhijiang Outstanding Young Scholar
Zhejiang Province 551 Talent Project Medical Rookie

Areas of Focus	Hematopoietic Stem Cell Transplantation
Publications	TP53 in MDS and AML: Biological and clinical advances, Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, Huang H(), Zhao Y(), 2024 Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma, Chen W, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Huang H(), Zhao Y(), 2024 Outcomes of haploidentical peripheral blood stem cell transplantation following myeloablative conditioning using two types of rabbit ATG: a propensity score-matched analysis, Shi Z, Gao F, Ding D, Wu H, Shi J, Luo Y, Yu J, Tan Y, Lai X, Liu L, Fu H, Huang H(), Zhao Y(), 2024 Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation, Gao F, Shi Z, Shi J, Luo Y, Yu J, Fu H, Lai X, Liu L, Yuan Z, Zheng Z, Huang H(), Zhao Y(), 2024 Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients, Huang J, Zhao Y, Jiang C, Han D, Pan Z, Zhang Z, Wang L, Chen W, Li S, Zhao Y(), Hu X(), 2023 Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis, Wu H, Zhao Y, Gao F, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Qian P, Huang H(), Zhao Y(), 2023 Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation, Gao Y, Wu H, Shi Z, Gao F, Shi J, Luo Y, Yu J, Lai X, Fu H, Liu L, Huang H, Zhao Y(), 2023 Interplay between metabolic reprogramming and post-translational modifications: from glycolysis to lactylation, Wu H, Huang H(), Zhao Y(), 2023 Altered intestinal microbiome and epithelial damage aggravate intestinal graft-versus-host disease, Gao F, Wu H, Wang L, Zhao Y(), Huang H(), 2023 The novel HLA-B15:644 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual, Shi ZY, Zheng ZZ, Du KM, Wu GQ, Zhao YM(), 2022 Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant, Wu H, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Ouyang G, Xu X, Xiao H, Huang H(), Zhao Y(), 2022 Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation, Gao F, Gao Y, Luo Y, Yu J, Fu H, Lai X, Liu L, Ye B, Lan J, Song X, Lu Y, Chen L, Chen Y, Yu K, Huang H(), Shi J(), Zhao Y(), 2021 Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation, Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, Fu H, Lai X, Liu L, Huang H(), 2021 Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients with Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation, Yanmin Zhao, Fei Gao, Yibo Wu, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Xiaoyu Lai, Mingming Zhang, Wei Zhang, He Huang(), 2021 Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation, Wu H, Shi J, Luo Y, Tan Y, Zhang M, Lai X, Yu J, Liu L, Fu H, Huang H(), Zhao Y(), 2021 Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation, Wu H, Cai Z, Shi J, Luo Y, Huang H(), Zhao Y(), 2021 Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation, Xu X, Li X, Zhao Y(), Huang H(), 2021 Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation, Gao Y, Gao F, Shi J, Fu H, Huang H(), Zhao Y(), 2021 HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells, He Y, Xu L, Feng J, Wu K, Zhao Y(), Huang H(), 2020 Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation, Fei Gao, Yishan Ye, Yang Gao, He Huang(), Yanmin Zhao(), 2020 Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia, Gao F, Zhou X, Shi J, Luo Y, Tan Y, Fu H, Lai X, Yu J, Huang H(), Zhao Y(), 2020 Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study, Zhao Y, Wu H, Shi J, Luo Y, Li X, Lan J, Ni W, Lu Y, Chen L, Tan Y, Lai X, Yu J, Huang H, 2020 Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation, Zhao, Yanmin; Shi, Jimin; Luo, Yi; Gao, Fei; Tan, Yamin; Lai, Xiaoyu; Yu, Jian; Wei, Guoqing(); Huang, He(), 2020 Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis, Yang, Apeng; Shi, Jimin; Luo, Yi; Ye, Yishan; Tan, Yamin; Huang, He(); Zhao, Yanmin(), 2019 Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation, Zhao, Yanmin; Gao, Fei; Shi, Jimin; Luo, Yi; Tan, Yamin; Lai, Xiaoyu; Yu, Jian; Huang, He(), 2020 Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis, Yanmin Zhao, Jimin Shi, Xiaoqing Li, Jiasheng Wang, Jie Sun, Jianfeng Zhou, He Huang(), 2020 Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia, Zhao, Yanmin; Wang, Jiasheng; Luo, Yi; Shi, Jimin; Zheng, Weiyan; Tan, Yamin; Cai, Zhen; Huang, He(), 2017 Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia, Wei, Guoqing; Wang, Jiasheng; Huang, He; Zhao, Yanmin(), 2017 Hydroxychloroquine sensitizes chronic myeloid leukemia cells to V gamma 9V delta 2 T cell-mediated lysis independent of autophagy, Han, Biqing; Zhao, Yanmin; Lin, Yu; Fu, Shan; Wang, Limengmeng; Zhang, Mingming; Tie, Ruxiu; Wang, Binsheng; Luo, Yi; Liu, Lizhen; Yu, Jian; Huang, He(*), 2017

Areas of Focus

Hematopoietic Stem Cell Transplantation

Publications

TP53 in MDS and AML: Biological and clinical advances, Zhao Y, Chen W, Yu J, Pei S, Zhang Q, Shi J, Huang H(*), Zhao Y(*), 2024
Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma, Chen W, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Huang H(*), Zhao Y(*), 2024
Outcomes of haploidentical peripheral blood stem cell transplantation following myeloablative conditioning using two types of rabbit ATG: a propensity score-matched analysis, Shi Z, Gao F, Ding D, Wu H, Shi J, Luo Y, Yu J, Tan Y, Lai X, Liu L, Fu H, Huang H(*), Zhao Y(*), 2024
Donor aKIR genes influence the risk of EBV and CMV reactivation after anti-thymocyte globulin-based haploidentical hematopoietic stem cell transplantation, Gao F, Shi Z, Shi J, Luo Y, Yu J, Fu H, Lai X, Liu L, Yuan Z, Zheng Z, Huang H(*), Zhao Y(*), 2024
Diagnostic efficiency of metagenomic next-generation sequencing for suspected infection in allogeneic hematopoietic stem cell transplantation recipients, Huang J, Zhao Y, Jiang C, Han D, Pan Z, Zhang Z, Wang L, Chen W, Li S, Zhao Y(*), Hu X(*), 2023
Haploidentical transplants deliver equal outcomes to matched sibling transplants: a propensity score-matched analysis, Wu H, Zhao Y, Gao F, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Qian P, Huang H(*), Zhao Y(*), 2023
Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantation, Gao Y, Wu H, Shi Z, Gao F, Shi J, Luo Y, Yu J, Lai X, Fu H, Liu L, Huang H, Zhao Y(*), 2023
Interplay between metabolic reprogramming and post-translational modifications: from glycolysis to lactylation, Wu H, Huang H(*), Zhao Y(*), 2023
Altered intestinal microbiome and epithelial damage aggravate intestinal graft-versus-host disease, Gao F, Wu H, Wang L, Zhao Y(*), Huang H(*), 2023
The novel HLA-B*15:644 allele, identified by Sanger dideoxy nucleotide sequencing in a Chinese individual, Shi ZY, Zheng ZZ, Du KM, Wu GQ, Zhao YM(*), 2022
Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant, Wu H, Shi J, Luo Y, Yu J, Lai X, Liu L, Fu H, Ouyang G, Xu X, Xiao H, Huang H(*), Zhao Y(*), 2022
Venetoclax plus hypomethylating agent for the salvage treatment of relapsing myeloid malignancies after hematopoietic stem cell transplantation: A multicenter retrospective study on behalf of the Zhejiang Cooperative Group for Blood and Marrow Transplantation, Gao F, Gao Y, Luo Y, Yu J, Fu H, Lai X, Liu L, Ye B, Lan J, Song X, Lu Y, Chen L, Chen Y, Yu K, Huang H(*), Shi J(*), Zhao Y(*), 2021
Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation, Zhao Y, OuYang G, Shi J, Luo Y, Tan Y, Yu J, Fu H, Lai X, Liu L, Huang H(*), 2021
Decreased iKIR-HLA C Pair Confers Worse Clinical Outcomes for Patients with Myeloid Disease Receiving Antithymocyte Globulin-Based Haploidentical Hematopoietic Stem Cell Transplantation, Yanmin Zhao, Fei Gao, Yibo Wu, Jimin Shi, Yi Luo, Yamin Tan, Jian Yu, Xiaoyu Lai, Mingming Zhang, Wei Zhang, He Huang(*), 2021
Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation, Wu H, Shi J, Luo Y, Tan Y, Zhang M, Lai X, Yu J, Liu L, Fu H, Huang H(*), Zhao Y(*), 2021
Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation, Wu H, Cai Z, Shi J, Luo Y, Huang H(*), Zhao Y(*), 2021
Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation, Xu X, Li X, Zhao Y(*), Huang H(*), 2021
Successful treatment of refractory pure red cell aplasia with eltrombopag after ABO-incompatible allogeneic hematopoietic stem cell transplantation, Gao Y, Gao F, Shi J, Fu H, Huang H(*), Zhao Y(*), 2021
HDAC Inhibitor LBH589 Suppresses the Proliferation but Enhances the Antileukemic Effect of Human γδT Cells, He Y, Xu L, Feng J, Wu K, Zhao Y(*), Huang H(*), 2020
Influence of KIR and NK Cell Reconstitution in the Outcomes of Hematopoietic Stem Cell Transplantation, Fei Gao, Yishan Ye, Yang Gao, He Huang(*), Yanmin Zhao(*), 2020
Eltrombopag treatment promotes platelet recovery and reduces platelet transfusion for patients with post-transplantation thrombocytopenia, Gao F, Zhou X, Shi J, Luo Y, Tan Y, Fu H, Lai X, Yu J, Huang H(*), Zhao Y(*), 2020
Ruxolitinib combined with etanercept induce a rapid response to corticosteroid-refractory severe acute graft vs host disease after allogeneic stem cell transplantation: Results of a multi-center prospective study, Zhao Y, Wu H, Shi J, Luo Y, Li X, Lan J, Ni W, Lu Y, Chen L, Tan Y, Lai X, Yu J, Huang H, 2020
Calcineurin Inhibitors Replacement by Ruxolitinib as Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation, Zhao, Yanmin; Shi, Jimin; Luo, Yi; Gao, Fei; Tan, Yamin; Lai, Xiaoyu; Yu, Jian; Wei, Guoqing(*); Huang, He(*), 2020
Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis, Yang, Apeng; Shi, Jimin; Luo, Yi; Ye, Yishan; Tan, Yamin; Huang, He(*); Zhao, Yanmin(*), 2019
Incidence, Risk Factors, and Outcomes of Primary Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation, Zhao, Yanmin; Gao, Fei; Shi, Jimin; Luo, Yi; Tan, Yamin; Lai, Xiaoyu; Yu, Jian; Huang, He(*), 2020
Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis, Yanmin Zhao, Jimin Shi, Xiaoqing Li, Jiasheng Wang, Jie Sun, Jianfeng Zhou, He Huang(*), 2020
Reduced-intensity allogeneic hematopoietic stem cell transplantation combined with imatinib has comparable event-free survival and overall survival to long-term imatinib treatment in young patients with chronic myeloid leukemia, Zhao, Yanmin; Wang, Jiasheng; Luo, Yi; Shi, Jimin; Zheng, Weiyan; Tan, Yamin; Cai, Zhen; Huang, He(*), 2017
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia, Wei, Guoqing; Wang, Jiasheng; Huang, He; Zhao, Yanmin(*), 2017
Hydroxychloroquine sensitizes chronic myeloid leukemia cells to V gamma 9V delta 2 T cell-mediated lysis independent of autophagy, Han, Biqing; Zhao, Yanmin; Lin, Yu; Fu, Shan; Wang, Limengmeng; Zhang, Mingming; Tie, Ruxiu; Wang, Binsheng; Luo, Yi; Liu, Lizhen; Yu, Jian; Huang, He(*), 2017

Hematopoietic Stem Cell Transplantation Gvhd Immunotherapy Targeted Therapy Hla Relapse Personalized Treatment Clinical Trials

Qi Zhang - Zhejiang University

Xia Dajing - Zhejiang University

Yunhua Liu - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us